Drug intelligence / Profile preview

cofetuzumab pelidotin + gedatolisib

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A combination of cofetuzumab pelidotin, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7), and gedatolisib, a dual PI3K/mTOR inhibitor. Cofetuzumab pelidotin consists of a humanized anti-PTK7 monoclonal antibody (hu6M024, IgG1) linked to an auristatin microtubule inhibitor payload (Aur0101).

Other names: Gedatolisib + PTK7-ADCGedatolisib and PTK7-ADCPTK7-ADCPTK-7-ADCPTK 7-ADC

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)PTK7 (Protein tyrosine kinase 7)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on cofetuzumab pelidotin + gedatolisib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cofetuzumab pelidotin + gedatolisib.

Explore the full profile